Patent: 10,786,557
Summary for Patent: 10,786,557
| Title: | Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Broom; Colin (Devon, PA), Dayno; Jeffrey (Maple Glen, PA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | SHIRE VIROPHARMA LLC (Lexington, MA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | 16/293,134 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Claims: | see list of patent claims | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims summary: | US Patent 10,786,557: Claims, Exclusivity, Litigation Risk and C1-INH Patent Landscape in Neuromyelitis OpticaUS Patent 10,786,557 protects a narrow clinical-use method: administering C1-esterase inhibitor during an acute neuromyelitis optica or neuromyelitis optica spectrum disorder attack and restoring symptoms to pre-attack levels. The patent does not claim C1-INH as a molecule, a formulation, a manufacturing process, or a broad treatment for complement-mediated disease. The principal commercial product implicated by the claims is Cinryze, a human plasma-derived C1-INH product. Cinryze is FDA-approved for routine prophylaxis against hereditary angioedema attacks, not for NMO or NMOSD. The patent therefore creates method-of-use exposure around off-label acute NMO treatment, but it does not create an Orange Book-style barrier against competing C1-INH products or biosimilars. What does US Patent 10,786,557 claim?The patent contains 18 claims directed entirely to methods of treatment or prevention. Independent claims 1 and 18 define the core scope.
The core infringement theory requires more than use of C1-INH in an NMO patient. The relevant treatment must satisfy the claimed disease, timing, therapeutic purpose and clinical-result limitations. What products fall within the patent claims?Claim 2 covers both:
Claim 4 narrows the use to Cinryze for NMO. The claim does not cover only Cinryze, however. Claim 1 is broader because it covers C1-INH generally, while claim 2 identifies plasma-derived and recombinant forms. The patent does not require a specific dose, route of administration, infusion schedule, concentration, formulation, device or treatment duration in the independent claims. That increases practical breadth within the defined acute-attack setting. How are the dependent claims structured?The dependent claims add disease subtypes, combination therapies and treatment timing.
Claim 3 is potentially important because it includes a long list of NMO-related clinical presentations, including AQP4-antibody-seronegative disease. Its breadth is limited by dependency on claim 1. The treatment still must involve C1-INH during an active attack and produce the claimed reduction in symptoms. Claims 5 through 15 create combination-treatment positions. They cover C1-INH with plasmapheresis, IVIG, mycophenolate, rituximab or eculizumab. They do not necessarily require that the additional treatment itself be novel. What is the patent’s likely expiration date?The patent issued in 2020 and claims priority to an earlier U.S. filing in the 2013 period. On the ordinary U.S. patent-term calculation, the family has a nominal expiration in the 2033-2034 range, subject to patent-term adjustment and any terminal disclaimer applicable to the issued patent family.[1]
The most reliable expiration date is the term information in USPTO Patent Center and the front-page patent-term statement. A patent issued from a continuation can retain the parent’s priority date while receiving a term measured from the earliest effective nonprovisional filing date. The grant date does not determine expiration. What is the FDA and Orange Book status of the patent?US Patent 10,786,557 is not an Orange Book product patent in the conventional sense. Cinryze is a biologic product regulated under a biologics license application, not an NDA-listed small-molecule product. FDA identifies Cinryze as a human plasma-derived C1-esterase inhibitor approved for routine prophylaxis against hereditary angioedema attacks.[2] The NMO use in US Patent 10,786,557 is not the approved indication. The relevant regulatory consequences are:
The patent can still be asserted against a provider, manufacturer or commercial sponsor whose conduct practices the claimed NMO treatment method. Its enforcement position is different from an Orange Book-listed method-of-use patent. Does Cinryze have FDA approval for NMO or NMOSD?No. Cinryze is approved for routine prophylaxis against hereditary angioedema attacks. The FDA label does not establish approval for acute NMO or NMOSD attacks.[2] C1-INH is biologically relevant to complement activation. NMO pathophysiology, particularly AQP4-antibody-positive disease, involves antibody-mediated astrocyte injury, complement activation and inflammatory damage. That mechanism provides a biological rationale for acute complement inhibition, but a mechanistic rationale is not equivalent to an FDA-approved indication. The commercial distinction is material:
What prior-art and validity issues affect the patent?The strongest validity questions concern the combination of known C1-INH biology, NMO complement activation and clinical use during acute attacks. Written description and enablementThe claims cover both treatment and prevention, multiple C1-INH sources, numerous NMO phenotypes and combinations with established therapies. A validity challenge could argue that the specification does not adequately support the full breadth of:
The counterargument is that the claims are treatment-method claims directed to a defined disease and a common biological mechanism, and that clinical examples or treatment protocols in the specification may support the claimed use. ObviousnessPotential prior art would include:
An obviousness challenge would need to show a reason to combine those teachings with a reasonable expectation that C1-INH would reduce acute NMO symptoms to pre-attack levels. The clinical-response limitation may provide the patentee with a stronger position if the record shows an unexpected or clinically meaningful result. IndefinitenessThe phrase “decreases symptoms of NMO or NMOSD to pre-attack levels” creates a potential indefiniteness issue. Symptoms such as visual acuity, motor strength, sensory loss and bladder dysfunction may be measured differently. The claim does not specify:
A court could interpret the phrase in light of the specification and ordinary clinical practice. If the patent provides objective pre-attack measurements or a defined assessment protocol, the vulnerability decreases. If not, the limitation may generate claim-construction and enablement disputes. Written description of claim 18Claim 18 is particularly exposed because it recites “preventing or delaying the progression” while also requiring administration at the onset of an active attack and a reduction of symptoms to pre-attack levels. A challenger may argue that the claim combines acute rescue treatment with a broader prophylactic objective that lacks adequate written-description support. How strong is the patent estate?The estate is commercially focused but technically narrow.
The patent does not prevent manufacture or sale of C1-INH for hereditary angioedema. It also does not prevent use of C1-INH for unrelated complement disorders. Its economic value depends on whether acute C1-INH treatment becomes accepted and commercially used for NMO or NMOSD. What formulations are protected by US Patent 10,786,557?No formulation-specific protection appears in the listed claims. The patent does not recite:
A competing manufacturer could therefore pursue a distinct formulation without avoiding the patent if it still practices the claimed NMO treatment method. Conversely, a formulation change alone may not avoid infringement if the product is administered in the claimed clinical setting. Which companies are challenging the patent?No conventional Paragraph IV challenge attaches to US Patent 10,786,557 because the patent is not an Orange Book-listed small-molecule patent. Publicly available patent records do not establish a reported Paragraph IV case directed to this patent. Potential commercial challengers would more likely be:
A biosimilar sponsor may avoid direct method infringement by labeling and promotion that exclude NMO, although physician prescribing and induced-infringement questions would depend on the product label, promotional conduct and actual use. What is the litigation status and settlement exposure?The patent’s principal litigation risk is method-of-use enforcement rather than product-market exclusion. A patentee would need to establish that the accused party:
The “pre-attack levels” requirement may complicate infringement proof. Medical records would likely be central. Evidence could include treatment protocols, physician instructions, infusion records, clinical trial materials, payer submissions and patient outcome assessments. Settlement agreements could include:
No public settlement should be treated as established without a court filing, SEC disclosure or company announcement. How does this patent compare with competing NMO drug estates?The patent has a different risk profile from approved NMO therapies.
The patent is most relevant to a treatment protocol that combines C1-INH with existing acute-care or maintenance therapies. It does not threaten the core composition claims, manufacturing claims or approved indications of competing monoclonal antibodies. What generic or biosimilar entry risks exist?Generic entry risk is low in the Hatch-Waxman sense because C1-INH products are biologics. Biosimilar entry risk is separate and depends on:
The patent could be asserted against a biosimilar sponsor whose label or promotional materials expressly recommend C1-INH for NMO. It is less likely to block a biosimilar marketed solely for hereditary angioedema if the sponsor avoids the claimed use. What are the commercial implications and revenue exposure?Revenue exposure is conditional rather than automatic. The patent does not cover the principal approved market for Cinryze, which is hereditary angioedema prophylaxis. Its value depends on whether NMO treatment becomes a reimbursed, protocolized use. The principal commercial variables are:
Approved NMO therapies with disease-specific labels may reduce the commercial importance of a C1-INH method patent unless C1-INH demonstrates a distinct acute-rescue benefit, lower cost or clinical utility in treatment-refractory attacks. Key Takeaways
FAQsCan Cinryze be used for NMO without infringing US Patent 10,786,557?Use during an acute NMO or NMOSD attack may fall within the patent claims if the other limitations are satisfied. Use for hereditary angioedema or an unrelated complement disorder is outside the stated claim scope. Does claim 4 prevent use of recombinant C1-INH for NMO?No. Claim 4 is limited to Cinryze, but claim 2, dependent on claim 1, covers human plasma-derived or recombinant C1-INH. Recombinant C1-INH may therefore raise issues under claims 1 and 2 if used in the claimed setting. Can a physician be liable for administering C1-INH during an NMOSD attack?Potentially, if the administration practices every limitation of an asserted claim. Direct infringement analysis would depend on the treatment facts, including timing, disease diagnosis and the claimed clinical outcome. Does the patent cover preventive maintenance treatment between NMO attacks?The claims focus on administration during an active attack or at attack onset. They do not clearly cover routine maintenance dosing between attacks absent facts bringing the treatment within the claim language. Are eculizumab and C1-INH interchangeable under this patent?No. Eculizumab is a different complement inhibitor and an approved NMOSD therapy. The patent becomes relevant only when C1-INH is administered in the claimed combination or treatment setting. References
More… ↓ |
Details for Patent 10,786,557
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | November 26, 1997 | ⤷ Start Trial | 2039-03-05 |
| Alexion Pharmaceuticals, Inc. | SOLIRIS | eculizumab | Injection | 125166 | March 16, 2007 | ⤷ Start Trial | 2039-03-05 |
| Takeda Pharmaceuticals U.s.a., Inc. | CINRYZE | c1 esterase inhibitor (human) | For Injection | 125267 | October 10, 2008 | ⤷ Start Trial | 2039-03-05 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
